BBA
EDSA icon

Braun-Bostich & Associates’s Edesa Biotech EDSA Stock Holding History

Braun-Bostich & Associates’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-446
Closed -$25K – 109
2020
Q3 		$25K Hold
446
– – 0.02% 193
2020
Q2 		$15K Hold
446
– – 0.01% 193
2020
Q1 		$7K Buy
+446
New +$9.17K 0.01% 233

Other funds holding EDSA

FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braun-Bostich & Associates's EDSA Position: Q4 2020 in Review

Braun-Bostich & Associates sold out of Edesa Biotech (EDSA) in Q4 2020, closing a stake of 446 shares — an estimated $25K sold.

Braun-Bostich & Associates first reported a position in EDSA in Q1 2020 and held it in 3 quarters. The position peaked at $25K in Q3 2020. 12 funds tracked by Wall St. Rank hold EDSA as of Q4 2020.

  • Braun-Bostich & Associates reported no remaining Edesa Biotech position as of Q4 2020 after selling out during the quarter.
  • Braun-Bostich & Associates sold 446 Edesa Biotech shares in Q4 2020, an estimated $25K.
  • Braun-Bostich & Associates first reported a position in Edesa Biotech in Q1 2020 and held it in 3 quarters.
  • Braun-Bostich & Associates's Edesa Biotech position peaked at $25K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Edesa Biotech as of Q4 2020.

Based on Braun-Bostich & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.